Tommie Vidales
Family · Levelland, TXNPI 1598964173
Payments from drug & device makers
Across 127 payments — averaging $16.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$516
- GSK$425
- AbbVie$414
- Novo Nordisk$259
- AstraZeneca$154
- Xeris Pharmaceuticals, Inc.$141
- plus $232 from 10 others
What the payments were for
- Food & beverage$2,140100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 33 | $516 |
| GSK | 30 | $425 |
| AbbVie | 21 | $414 |
| Novo Nordisk | 11 | $259 |
| AstraZeneca | 8 | $154 |
| Xeris Pharmaceuticals, Inc. | 7 | $141 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $87 |
| Nestle Healthcare Nutrition Inc. | 2 | $27 |
| Boehringer Ingelheim | 2 | $26 |
| Hikma Pharmaceuticals USA | 1 | $18 |
| Merck | 1 | $17 |
| Biogen | 1 | $15 |
| Amgen | 1 | $13 |
| Abbott | 1 | $13 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Organon | 1 | $3 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,140 in reported general payments places this provider in the 80th percentile of 15,456 family providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 205 | $243,652 |
| JardianceEmpagliflozin | 260 | $190,024 |
| JanuviaSitagliptin Phosphate | 170 | $123,160 |
| OzempicSemaglutide | 111 | $111,900 |
| EliquisApixaban | 116 | $93,946 |
| Tresiba Flextouch U-200Insulin Degludec | 41 | $56,042 |
| XifaxanRifaximin | 13 | $46,096 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $45,593 |
| TrulicityDulaglutide | 39 | $43,559 |
| FarxigaDapagliflozin Propanediol | 42 | $33,433 |
| LinzessLinaclotide | 38 | $26,443 |
| Tresiba Flextouch U-100Insulin Degludec | 30 | $22,189 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 28 | $20,764 |
| JanumetSitagliptin Phos/Metformin Hcl | 26 | $20,611 |
| MyrbetriqMirabegron | 36 | $19,715 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $516 | $287,211244 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Combivent Respimat, Tradjenta | $26 | $237,439321 claims |
| MerckJanuvia, Janumet, Janumet Xr | $17 | $155,736214 claims |
| Novo NordiskOzempic | $259 | $111,900111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $425 | $51,20180 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $154 | $46,89064 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $87 | $46,09613 claims |
| AbbVieLinzess | $414 | $26,44338 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 15,456 family providers in Texas.
Other family in Levelland
- Lashonda CraneHouston$3.4M
- David WeirDallas$959K
- Luba YammineHouston$479K
- Robin BeachHouston$428K
- Nirupama JeromeAustin$418K
- April LopezMcAllen$417K
- Linda MercadoHouston$211K
- Sarah AguilarHouston$199K
- Sie ThomasDallas$197K
- Anna CastroSan Antonio$184K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.